Merkel cell carcinoma (MCC) is a rare and highly aggressive skin cancer associated with the Merkel cell polyomavirus (MCV). As MCC cell lines show oncogene addiction to the MCV T antigens, pharmacologic interference of the large T antigen (LTA) may represent an effective therapeutic approach for this deadly cancer. In this study, we investigated the effects of IFNs on MCC cell lines, especially on MCV-positive (MCV þ ) lines. Type I IFNs (i.e., Multiferon, a mix of different IFN-a subtypes, and IFN-b) strongly inhibited the cellular viability. Cellcycle analysis showed increased sub-G fractions for these cells upon IFN treatment indicating apoptotic cell death; these effects were less pronounced for IFN-g. Notably, this inhibitory effect of type I IFNs on MCV þ MCC cell lines was associated with a reduced expression of the MCV LTA as well as an increased expression of promyelocytic leukemia (PML) protein, which is known to interfere with the function of the LTA. In addition, the intratumoral application of Multiferon resulted in a regression of MCV þ but not MCV À MCCs in vivo. Together, our findings show that type I IFNs have a strong antitumor effect, which is at least in part explained by modulation of the virally encoded LTA. Cancer Res; 72(8); 2120-8. Ó2012 AACR.
Introduction
Merkel cell carcinoma (MCC) which is also known as neuroendocrine carcinoma of the skin is a rare, highly aggressive skin cancer, with a strong and continuous increase in incidence over the past years (1) . UV exposure and immune suppression are known risk factors for MCC (2) . Indeed, MCC is much more frequent in severely immunosuppressed populations caused by immune suppressive drugs in organ transplant patients, lymphoma, or HIV infection (3) . In accordance with the notion that many cancers with infectious etiologies are more prevalent in the context of immunosuppression, the Merkel cell polyomavirus (MCV) was identified clonally integrated in the genome of most MCC cells (4) . Meanwhile, many studies confirmed the association of MCC with MCV (5, 6) . MCV encodes the potential oncoproteins small and large Tantigen (LTA; ref. 7) . Notably, it has been shown that the maintenance of MCV-positive (MCV þ ) MCC cell lines critically depends on the presence of MCV LTA sustaining the role of MCV in the pathogenesis of MCC (8, 9) . IFN has been first described as secreted macromolecule produced by cells after treatment with heat-inactivated influenza virus (10) . Indeed, IFNs are a large family of multifunctional, secreted proteins which have antiviral, antitumoral, and immune modulating effects mediated through IFN-stimulated gene (ISG) expression (11) . Three types of IFNs have been described in mammalians. Type I IFNs (a, b, e, k, n, and w) as well as type III IFN (IFN-l1-3; ref. 12 ) are produced ubiquitously in response to viral infection, double-stranded RNA, or other stimuli. In contrast, type II IFN-g is only induced in activated T lymphocytes and natural killer cells (11, 13) . The biologic activities of IFNs are initiated by binding to their cognate receptors, that is, predominantly the IFN-a/b receptor for type I, the IFN-g receptor for type II, and the IL10R2/IFNLR1 for type III IFN. Upon binding to the respective receptors different signal cascades are activated. The classical Janusactivated kinase (Jak)/STAT pathway leads to the transcription of a distinct set of genes which mediate the biologic effects of these cytokines, that is, antiproliferative effects and antiviral activity for type I and III IFNs and immune modulatory effects for type II IFNs (11) . It is important to note, however, that the cellular responses to engagement of the IFN receptors are subject to several modulating factors, for example, the activation status of the cells, binding of other cytokines/chemokines, or environmental factors such as hypoxia.
The therapeutic use is currently largely restricted to type I IFNs. For example, recombinant IFN-a2 has been U.S. Food and Drug Administration approved for the therapy of hairy cell leukemia or adjuvant therapy of melanoma (14, 15) . In addition, IFN-a is used for the treatment of hepatitis B and C and HIV-associated Kaposi sarcoma whereas IFN-b is used for therapy of multiple sclerosis (16) (17) (18) .
The antiviral activity of type I IFNs has also been investigated for polyomaviruses. In this regard, type I IFNs can both limit the replication of John Cunningham (JC) virus and interfere with expression of virally encoded genes (19) . Similarly, IFN-g is able to suppress BK virus gene expression (20 
Materials and Methods

Ethics statement
The presented work was conducted according to the principles expressed in the Declaration of Helsinki. The generation and characterization of MCC cell lines was approved by the Institutional Review Board of University Hospital W€ urzburg (sequential study number 124/05). All the animal experiments were approved by the local authorities (Regierung von Unterfranken; animal experiment request Az. 55.2-2531.01-59/06) according to the legal requirements.
Cell culture
The MCV þ cell lines WaGa, BroLi, MKL-1, and MKL-2 as well as the MCV À MCC cell lines UISO, MCC13, and MCC26 (25) (26) (27) have been described previously. For doxycycline inducible T-antigen knockdown, retroviral-infected MKL-1 piH TA tet, MKL-2 piH TA tet, and WaGa piH TA tet cell lines (9) were used. All cell lines were grown in RPMI-1640 medium (PAN Biotech) supplemented with 10% FBS (Biochrom AG), 100 U/mL penicillin and 0.1 mg/mL streptomycin (Sigma Aldrich).
Animal experiments
Five-week-old female NOD.CB17/Prkdc scid mice were obtained from Harlan Winkelmann and housed under specific pathogen-free conditions. Tumors were induced by s.c. injection of 5 Â 10 6 cells/100 mL mixed 1:1 with MatriGel Matrix (Becton Dickinson) into the lateral flank of the mice. Multiferon (Swedish Orphan) treatment was started 10 days after cellular injection. A total of 10,000 units of Multiferon in 50 mL PBS (PAN Biotech) or 50 mL PBS were injected intratumorally every day (n ¼ 6 for each group) as previously described (28) .
Immunoblotting
Cell lysates of MCV þ MCC cell lines cultured for 4 days in 24-well plate at 1 Â 10 6 cells per well with 50,000 units/mL Multiferon; or IFN-b (PeproTech) or 10,000 units/mL IFN-g (PeproTech) were generated as previously described (9) . After SDS-PAGE, samples were transferred to nitrocellulose membranes (GE Healthcare), blocked 1 hour with PBS (Sigma Aldrich), containing 0.05% PBS-Tween 20 (PBS-T) supplemented with 5% powdered skim milk and then incubated overnight with a primary antibody. Following 3 washing steps with PBS-T, membranes were incubated with a peroxidase-coupled secondary antibody (DAKO) followed by use of the Plus-ECL Chemiluminescence Detection Kit (Thermo Scientific). Antibodies used were CM2B4 (1:1,000) for MCV LTA protein, H-238 rabbit polyclonal antibody (1:200) for PML (both Santa Cruz Biotechnologies), and TUB 2.1 (1:2,500; Sigma Aldrich) for b-tubulin.
MTS assay
Cell proliferation, metabolism, and viability were measured with the MTS cell assay (Promega) according to the manufacturer's instructions. MCC cell lines were cultured in triplicates at 1,000 (MCC 13, MCC26), 3,000 (UISO), 10,000 (WaGa), or 80,000 (BroLi, MKL-1, MKL-2) cells per well with 0, 781, 3,125, 12,500, or 50,000 units/mL of type I or 0, 156, 625, 2,500, and 10,000 units/mL of type II IFN for 7 days. Cell proliferation of MCV þ cells upon T-antigen knockdown was determined by culture of the respective cells for 5 days in the presence of 1 mg/mL doxycycline (Sigma Aldrich).
Cell-cycle analysis
For cell-cycle analysis, 5 Â 10 5 (MCC13, MCC 26, and UISO) or 1 Â 10 6 (MKL-1, MKL-2 WaGa, and BroLi) cells per well were cultured for 7 days with 50,000 units/mL Multiferon or IFN-b or 10,000 units/mL IFN-g. Single-cell suspensions were fixed with 5 mL of ice-cold ethanol (100%) overnight at 4 C; cell pellets were resuspended in 1 mL PBS supplemented with 1% fetal calf serum (FCS), 0.05 mg/mL propidium iodide (PI; Sigma Aldrich), and 0.1 mg/mL RNase A (Fermentas) and incubated for 1 hour at 37 C. Flow cytometry was conducted on a FACSCanto flow cytometer and analysis made with FlowJo analysis software (Tree Star Inc.).
Immunohistochemistry and immunofluorescence
Immunohistochemistry on formalin-fixed and paraffinembedded tissue was carried out as previously described (9) . For antigen recovery, deparaffinized sections were incubated with DAKO Target Retrieval Solution (DAKO), pH 9.0 for 40 minutes at 90 C and rinsed twice with bidistilled water and once with PBS, incubated with blocking solution (DAKO) at room temperature and after 2 additional washes stained overnight with a rabbit monoclonal antibody specific for cleaved caspase-3 (D178; 1:2,000; Cell Signaling). Detection of the antibody was conducted with Dako Envision-HRP (DAKO) and Nova Red Substrate Kit (Vector Laboratories) following the manufacturer's protocol. To show possible interaction of PML and LTA the Duolink system was used according to the manufacture's protocol (Olink Bioscience). For microscopy, a Leica DM750 microscope with ICC50 digital microscope camera (Leica) was used.
For immunofluorescence, cytospins of 6 Â 10 4 WaGa cells cultured with 3,500 units of Multiferon per mL for 3 days or of untreated cells, respectively, were fixed in acetone for 10 minutes, rinsed with PBS, and incubated with blocking solution (DAKO) for another 10 minutes. After another washing step, cells were stained first with PML H-238 rabbit polyclonal antibody (1:100; Santa Cruz Biotechnologies) and with Cy3-labeled goat anti-rabbit IgG (HþL) secondary antibody (1:200; Dianova) each for 45 minutes. Slides were mounted with Vectashield with DAPI (Vector Laboratories) and analyzed with TCS SP2 confocal fluorescence microscope (Leica).
Statistical analysis
Statistical analysis was conducted with Prism 5.03 (GraphPad Software, Inc. Fig. 1 ). The strongest inhibition was reduction of cellular viability after 5 days compared with untreated control group (P ¼ 0.031; Fig. 3) . Consequently, we next tested whether the observed effects of type I IFNs on MCV þ MCC cell lines were mediated by a downregulation of LTA expression. Determination of protein expression of MCV LTA in MCC cell lines after 7 days of incubation with type I and type II IFNs revealed a decrease in LTA expression in response to treatment with type I IFNs for all cell lines analyzed; this downregulation is particularly pronounced for Multiferon (Fig.  4A) . In contrast, incubation with IFN-g leads only in WaGa cells to a reduced expression level of MCV LTA.
Induction of the PML protein by IFNs
In addition to the negative regulation of the LTA expression, a number of proteins that interfere with the oncogenic proteins of viruses are regulated particularly by type I IFNs. The most prominent of these with respect to an impaired LTA function is the PML protein. Indeed, we could show by Western blot analysis that PML is highly upregulated in MCC cells upon treatment with IFNs (Fig. 4A) . With the exception of WaGa cells, type I IFNs cause a stronger PML induction than IFN-g. This induction of PML by type I IFN was further showed by immunofluorescence of untreated or IFN-treated WaGa cells. Here, a marked increase in the number of PML nuclear bodies was obvious (Fig. 4B) .
Antitumor activity of Multiferon against MCC in vivo
To translate these observations into the in vivo situation, we took advantage of recently established xenotransplantation (Fig. 5B) ; thus, the observed in vivo effects of Multiferon are not only due to an impaired proliferation but also to an increased rate of apoptosis. This notion is in line with both with the in vitro findings as well as the active regression of the established tumors subsequent to Multiferon treatment. Our in vitro data suggests that PML might contribute to the regression of the tumors. In order to further expand this observation we conducted Duolink analysis to determine whether PML would interact with LTA; this technique generates positive signals only if the proteins are in close proximity (29) . Analysis of MCV þ WaGa xenografts did indeed reveal positive signals primarily in the nucleus showing a colocalization of PML and LTA in WaGa cells (Fig. 5C) .
As a control, we could not observe such an interaction in MCV À UISO xenografts.
Discussion
Since their discovery in 1957 by Isaacs and Linderman (10), IFNs are regarded as drugs with a potential to treat cancer. Because of their ability to directly or indirectly interfere with the expression or function of oncogenic viral proteins, IFNs also seem to be particularly suitable to treat virally induced cancers. In the present report, we scrutinized the effects of type I and II IFNs on MCC, a highly aggressive skin cancer for which the viral oncogenesis has recently been indicated.
The impact of IFNs on MCC cells is characterized by an impaired proliferation, metabolism, and viability particularly after type I IFN treatment; these effects were much more pronounced in MCV þ cell lines and largely associated with the induction of apoptosis. Notably, however, in the case of the MCV þ cell line MKL-1 the strong inhibiting effect of type I IFNs was not associated with the induction of apoptosis. Interestingly, a similar observation has been reported for human lung carcinoma cells (30) . It should be further noted that the BroLi cell line harbors a significant proportion of apoptotic cells already in the untreated control group. This observation suggests that MCV infection itself may render cell prone to apoptosis. Indeed, MCC since its initial description by Toker (31) has been known for its high rate of apoptosis (32) . For several DNA viruses, including polyomaviruses, induction of apoptosis of the infected cell is part of the viral replication cycle ensuring the release of the virions. This host cell apoptosis is initiated by expression of the very late viral protein (33) , which, however, has not been elucidated for MCV yet. It should be further noted, that specific miRNAs have been suggested to be involved in MCV virion release (34) . As mentioned earlier, recent reports described that IFN-g treatment interferes with LTA expression in BK virus-infected cells (20) and that type I IFNs interfere with LTA expression in JC virus-infected cells (19) (21) . This effect is based on a functional inhibition of LTA due to trapping of this protein within PML nuclear bodies via interaction the conserved LXCXE amino acid motif common to all viral oncoproteins that bind pRB (9, 35) . In general, the antiviral activity of PML and PML nuclear bodies are well established (21, (36) (37) (38) (45, 46) . Another report showed the suppression of insulin-like growth factor-binding protein 7 (IGFBP7) in IFN-a resistant hepatocellular carcinoma (HCC) cells (47) . However, the crucial mechanism remains unknown. Further possible mechanisms for IFN resistance could be mediated by miRNAs. Actually, it was recently described that sensitivity of HCC cells toward IFN-a is regulated by miRNA-146a targeting the SMAD4 protein (48) . All these reports illustrate the diversity of mechanisms underlying IFN resistance. Which of these multiple mechanisms mediates insensitivity in the 2 MCC cell lines has yet to be determined. In summary, the present work provides several lines of evidence that IFNs, particular type I IFNs, exert direct inhibitory effects on MCC cell lines in vitro and in vivo. Mechanistically, this effect seems largely due to an induction of apoptotic cell death. Treatment of MCC cell lines with the different IFNs inhibited the expression of virally encoded LTA and induced the expression of PML, which has been previously showed to interfere with the functional activity of the LTA. Consequently, based on the here presented data as well as the well established immunomodulating effects of IFNs such as reinduction of MHC class I molecules or the activation of immune competent cells, treatment of MCC with type I IFNs appears as a promising therapeutic option for patients with MCC; a notion substantiated by several case reports on successful therapy of metastatic MCC lesions by localized type I IFN therapy; thus, these observations are advocating the investigation of especially type I IFNs for therapy of MCC in clinical trials. 
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